We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: pembrolizumab
MedXY News
EnglishTag

pembrolizumab

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical Trial
newschemotherapyKEYNOTE-826

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical Trial

By MedXY|Sep 15, 2026

Five-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.

Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck Cancer
newsimmune checkpoint inhibitors
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Quad-Shot Radiotherapy

Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck Cancer

By MedXY|Aug 21, 2026

A phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels
newsCost-Effectivenessimmunotherapy

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

By MedXY|Aug 11, 2026

The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.

Pembrolizumab Combined with Radiotherapy Shows Promise in Advanced Cutaneous T-Cell Lymphoma: Final Results from UK NCRI Phase II Trial
Hematology-OncologyCutaneous T-Cell LymphomaRadiotherapy

Pembrolizumab Combined with Radiotherapy Shows Promise in Advanced Cutaneous T-Cell Lymphoma: Final Results from UK NCRI Phase II Trial

By MedXY|Aug 10, 2026

The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcome

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma
newsimmune checkpoint inhibitorsrecurrent vulvar cancer

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma

By MedXY|Aug 18, 2026

This retrospective study found that immune checkpoint inhibitors produced modest overall benefit in recurrent vulvar and vaginal carcinoma, but a small subset of patients had durable responses lasting months.

Cost-effectiveness of Pembrolizumab for FIGO 2014 Stage III-IVA Cervical Cancer in the United States
newsCost-Effectivenesspembrolizumab

Cost-effectiveness of Pembrolizumab for FIGO 2014 Stage III-IVA Cervical Cancer in the United States

By MedXY|Aug 18, 2026

Pembrolizumab plus chemoradiotherapy improved survival and quality-adjusted survival for FIGO 2014 stage III-IVA cervical cancer and was projected to be cost-effective in the U.S. at a $150,000/QALY threshold.

Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer
newshead and neck cancerimmunotherapy

Immunotherapy Prescribing Patterns and Immune-Related Adverse Events in Head and Neck Cancer

By MedXY|Apr 27, 2026

A large claims-based study reveals pembrolizumab dominates immunotherapy prescribing for head and neck cancer, with minimal usage growth since FDA approval. Immune-related adverse events occurred in 41.2% of patients, linked to specific com

Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge
newsimmunotherapyNon-Small Cell Lung Cancer

Long-Term NSCLC Survivors After Pembrolizumab Show High Survival Rates, Rare Immunotherapy Rechallenge

By MedXY|Apr 14, 2026

A nationwide French cohort study reveals that advanced NSCLC patients completing 2 years of pembrolizumab maintain excellent survival outcomes, with most remaining treatment-free and immunotherapy rechallenge being uncommon.

KEYVIBE-010: Why Adding TIGIT Inhibition to Pembrolizumab Failed to Benefit High-Risk Resected Melanoma Patients
Dermatologyimmunotherapymelanoma

KEYVIBE-010: Why Adding TIGIT Inhibition to Pembrolizumab Failed to Benefit High-Risk Resected Melanoma Patients

By MedXY|Mar 2, 2026

The Phase 3 KEYVIBE-010 trial demonstrates that adding vibostolimab to pembrolizumab in the adjuvant setting for melanoma does not improve outcomes, instead yielding a higher recurrence rate and increased toxicity, reinforcing pembrolizumab

Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
newsenfortumab vedotinoncology

Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

By MedXY|Feb 22, 2026

The Phase 3 KEYNOTE-905/EV-303 trial demonstrates that perioperative enfortumab vedotin plus pembrolizumab significantly improves event-free survival (HR 0.40) and overall survival (HR 0.50) compared to surgery alone in cisplatin-ineligible

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice
newsadverse eventshead and neck cancer

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice

By MedXY|Feb 19, 2026

A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specif

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC
newsantibody-drug conjugatespembrolizumab

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC

By MedXY|Jan 25, 2026

The phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrates that sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival and duration of response compared to standard chemotherapy plus pembrolizumab in patients wi

Radiotherapy-Free Pembrolizumab and Chemotherapy Challenge the Standard of Care in PD-L1 High Locally Advanced NSCLC
newsimmunotherapyNSCLC

Radiotherapy-Free Pembrolizumab and Chemotherapy Challenge the Standard of Care in PD-L1 High Locally Advanced NSCLC

By MedXY|Jan 13, 2026

The Phase 2 Evolution trial suggests that for unresectable, locally advanced NSCLC with PD-L1 TPS ≥50%, a radiotherapy-free regimen of pembrolizumab plus chemotherapy is feasible, yielding a 67% 2-year progression-free survival rate and a m

KEYLYNK-009: Is Olaparib Plus Pembrolizumab a Viable Maintenance Strategy in Metastatic Triple-Negative Breast Cancer?
newsBRCA突变olaparib

KEYLYNK-009: Is Olaparib Plus Pembrolizumab a Viable Maintenance Strategy in Metastatic Triple-Negative Breast Cancer?

By MedXY|Jan 11, 2026

The KEYLYNK-009 trial investigated pembrolizumab plus olaparib as maintenance therapy for metastatic TNBC. While it did not meet primary PFS or OS endpoints compared to chemotherapy, the combination showed a favorable trend in BRCA-mutated

Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial
newsfinancial toxicityimmunotherapy

Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial

By MedXY|Jan 8, 2026

The PLANeT trial demonstrates that low-dose pembrolizumab (50 mg) plus chemotherapy significantly improves pathological complete response rates in triple-negative breast cancer, offering a high-efficacy, cost-effective alternative for resou

Neoadjuvant Pembrolizumab Plus Chemoradiotherapy Yields 43.2% pCR in Resectable ESCC — IL-6 Emerges as a Predictive Biomarker
newsesophageal squamous cell carcinomaIL-6

Neoadjuvant Pembrolizumab Plus Chemoradiotherapy Yields 43.2% pCR in Resectable ESCC — IL-6 Emerges as a Predictive Biomarker

By MedXY|Dec 9, 2025

The multicenter PALACE-2 trial reports a 43.2% pathological complete response (pCR) with preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma and identifies baseline serum IL-6 as a po

Low‑Dose IL‑2 after Lymphodepletion and TIL Infusion Offers Comparable Immune and Clinical Outcomes to High‑Dose IL‑2 in Metastatic Melanoma
newsinterleukin-2pembrolizumab

Low‑Dose IL‑2 after Lymphodepletion and TIL Infusion Offers Comparable Immune and Clinical Outcomes to High‑Dose IL‑2 in Metastatic Melanoma

By MedXY|Dec 6, 2025

A phase II study in metastatic melanoma found no major differences in response, circulating T‑cell phenotypes, or proliferative signals between high‑dose and low‑dose IL‑2 after lymphodepletion and tumor‑infiltrating lymphocyte (TIL) infusi

Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights
newsesophageal squamous cell carcinomaneoadjuvant immunotherapy

Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights

By MedXY|Dec 1, 2025

PALACE‑2 reports that preoperative pembrolizumab combined with chemoradiotherapy produced a 43.2% pathologic complete response in resectable, locally advanced esophageal squamous cell carcinoma, with acceptable short‑term survival and a hig

Pembrolizumab plus Lenvatinib Shows Promising Activity but Substantial Toxicity as Second-Line Therapy After Nivolumab–Ipilimumab in Pleural Mesothelioma
newsimmunotherapylenvatinib

Pembrolizumab plus Lenvatinib Shows Promising Activity but Substantial Toxicity as Second-Line Therapy After Nivolumab–Ipilimumab in Pleural Mesothelioma

By MedXY|Nov 29, 2025

In a single‑arm phase 2 cohort, pembrolizumab plus lenvatinib produced a 60% objective response rate in 20 patients with pleural mesothelioma progressing after first‑line nivolumab plus ipilimumab, but grade 3–4 toxicities were frequent (70

Perioperative Pembrolizumab + Trastuzumab with FLOT Achieves High pCR and Feasible Safety in HER2‑Positive Localized Esophagogastric Adenocarcinoma: Interim PHERFLOT Results
General SurgeryFLOTpembrolizumab

Perioperative Pembrolizumab + Trastuzumab with FLOT Achieves High pCR and Feasible Safety in HER2‑Positive Localized Esophagogastric Adenocarcinoma: Interim PHERFLOT Results

By MedXY|Nov 12, 2025

Interim results from the phase 2 PHERFLOT trial show a 48.4% pathological complete response and a 67.7% major pathologic response after four cycles of pembrolizumab, trastuzumab and FLOT in localized HER2‑positive esophagogastric adenocarci

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities